PAYS Earnings

PAYS reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 22.00M against an estimate of 20.00M, resulting in a 8.44% surprise. The EPS was 0.04, surpassing the expected 0.04 by 0% . The stock experienced a 0% price change on the earnings day and a -5.85% change over the next five days, reflecting market reactions to the results.

Following PAYS's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by 0.00% on the day of the release. Over the subsequent five days, it saw a -5.85% change. Historically, PAYS's stock price tends to shift by an average of -2.94% in the 10 days leading up to earnings and -2.88% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate PAYS’s annual revenue to reach 22.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.41% and EPS estimates Revise Downward by -0.26% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PAYS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 3.41%, while EPS estimates moved Revise Downward by -0.26% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PAYS's stock price typically moves by -2.94% in the 10 days before its earnings and -2.88% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 22.00M.

The earnings call indicates strong growth prospects, with significant year-over-year improvements in financial metrics, increased revenue guidance, and operational efficiencies. The Q&A section supports optimism with plans for new programs and systems, despite management's lack of specific details. The raised revenue guidance and anticipated FDA approval for new systems suggest positive momentum. However, the lack of clear guidance on some metrics and confidentiality constraints slightly temper the outlook, preventing a 'Strong positive' rating.